Dr. Cheng Discusses RICTOR Amplification in Lung Cancer

Haiying Cheng, MD
Published: Friday, Aug 08, 2014

Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Care, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.

Cheng says RICTOR, a key component of the mTOR protein complex, was first identified in 2004. After examining two databases in which patients with lung cancer had undergone next-generation sequencing, it was found that about 8% of patients had RICTOR amplification. Only 11% of patients found to have RICTOR amplification had the amplification as their sole actionable target, Cheng says.

Cheng says several compounds were tested but it was found that mTOR1/2 inhibitors are the most active against the amplification.

Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Care, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.

Cheng says RICTOR, a key component of the mTOR protein complex, was first identified in 2004. After examining two databases in which patients with lung cancer had undergone next-generation sequencing, it was found that about 8% of patients had RICTOR amplification. Only 11% of patients found to have RICTOR amplification had the amplification as their sole actionable target, Cheng says.

Cheng says several compounds were tested but it was found that mTOR1/2 inhibitors are the most active against the amplification.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x